Abiopharma

🔍 Lucas Bruce (Executive)

Company: Slide Insurance Holdings, Inc. (SLDE)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Sold 173,317 shares of Common Stock at $18.81 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: false | shares_owned_after: 36,245,046.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 91,000 shares of Common Stock at $18.76 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: false | shares_owned_after: 36,154,046.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | shares_owned_after: 1,151,445.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 220,000.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 1,281,992.00 | Footnotes: F6, F7
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By Emma Cloonen Irrevocable Trust | shares_owned_after: 1,925,000.00 | Footnotes: F8
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By Ava Cloonen Irrevocable Trust | shares_owned_after: 1,925,000.00 | Footnotes: F9

Footnotes:

• F1: Sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2025.
• F2: Represents the weighted average price of the shares sold. The prices of the shares sold pursuant to the transactions ranges from $18.75 to $18.90 per share. The Reporting Person, upon request, will provide the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
• F3: The securities reported herein are held by IIM Holdings II, LLC, which is an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
• F4: Represents the weighted average price of the shares sold. The prices of the shares sold pursuant to the transactions ranges from $18.75 to $18.91 per share. The Reporting Person, upon request, will provide the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
• F5: Represent shares of common stock beneficially owned by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
• F6: The amount shown reflects the amount owned by the Reporting Person's spouse after the sale of 26,141 shares of common stock between May 7-11, 2026, pursuant to a 10b5-1 trading plan, at prices ranging from $18.75 to $18.91 per share.
• F7: Represent shares of common stock beneficially owned by the Reporting Person's spouse through Securus Risk Management LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
• F8: Represent shares held through the Emma Cloonen Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
• F9: Represent shares held through the Ava Cloonen Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
• REMARKS: The Reporting Person previously reported 2,575,837 shares held indirectly by the Bruce Lucas Irrevocable Grantor Retained Annuity Trust of 2014 (the "Trust") which should not have been reported in his Form 3 and subsequent Form 4s, as neither the Reporting Person nor his spouse have direct or indirect beneficial ownership of the shares of the Issuer's common stock reported as held indirectly by the Trust.